Funding Acknowledgements Type of funding sources: None. Introduction Electrical cardioversion (DCCV) is a long-used and proven method for the acute termination of atrial fibrillation episodes. The methodology for optimal performance of DCCV with the highest level of effectiveness while maintaining maximum safety is still under investigation. To validate our proposed methodology for performing DCCV, we have initiated the PROTOCOLENERGY clinical trial, which is currently ongoing. Objective To test the effect of conducting a clinical trial on the effectiveness of cardioversion in patients who were not included in the study for any reason. Methodology A retrospective analysis of the DCCV registry from the indications of persistent atrial fibrillation (long-term persistent excluded) from 2015-8/2022. Statistical comparison of the demographics and overall effectiveness of the DCCV cohort before and after study initiation and comparison of the cohort, enrolled and not enrolled since study initiation (no interim analysis of the study cohort proper). Heart rate 1 min after the last discharge is assessed. Cohort A total of 2402 procedures were analyzed in 829 women (34.5%) and 1573 men (65.5%) aged 67 (+/-10) years, with CHADSVASC score of 3,0 (+/− 1), BMI 31.2 (+/-7.7). Results DCCV efficiency in the whole cohort was 91.1%. Before the study, SR was achieved in 90% of the 1981 patients; since the start of the clinical trial, DCCV efficacy increased to 96.4% (in a cohort of 421 patients) (p <0.001). There was no statistically significant effect in efficacy between patients included in the clinical trial (312 pt.) and those not included (109 pt.) (96.5% vs. 96.3% p=0.944). Conclusion The presented data suggest an effect of developing and controlling the methodology of DCCV performance in a clinical trial on increasing the efficacy of DCCV, even in the cohort of patients not enrolled in the clinical trial. That phenomenon is called the HAWTHORNE effect and is related to the improvement of the outcome of the investigated phenomenon due to the influence of the actual investigation. In this case, probably due to strict adherence to the study protocol ( paddle pressure during DCCV, cardioversion in expiration, adherence to predetermined cardioversion energies, etc. even in patients not included in the study).
Background Electrical cardioversion (DCCV) is an effective method of sinus rhythm restitution. Recently published data suggest higher efficiencies of higher discharge energies. The influence of individual parameters on the success of cardioversion is still studying. Purpose To evaluate the influence of individual patient parameters on the energy of a successful external defibrillator shock during cardioversion of atrial arrhythmias Methods The retrospective analysis cohort of all patients treated by DCCV due to atrial arrhythmias between 10/2015 and 1/2020. To evaluate potential predictors for the choice of a higher initial discharge using one-dimensional logistic regression and to include parameters significant at the 10% level of significance (p<0.1) in the multidimensional logistic regression model. Results 1986 electrical cardioversions of 984 patients (382 repeated procedures of the same patients in a cohort). 1292 (65.1%) men and 694 (34.9%) women aged 67.0 (±10.2) years. Mean energy of the first shock 118.9 (±19.2) J with a success rate of 77.8%, energy of the second shock 154.0 (±26.3) J, which increased the overall success to 80.0%, and mean high of the third shock 173.9 (±25.6) J, when the total efficacy of DCCV in sinus rhytm restitution reached 89.8%. From the univariate binary regression, parameters significant at the 10% level of significance (p<0.1) were selected and included in a multidimensional logistic regression model. Only the patient's weight and the use of amiodarone proved to be statistically significant. Weight with OR 1.21 and use of amiodarone with OR 1.43. Conclusion Patient weight and amiodarone use are predictors of the need to use higher energy electric cardioversion. Discussion Amiodarone medication does not appear to increase the defibrillation threshold, but rather is a feature that represents the group of patients treated with more aggressive antiarrhythmic therapy for advanced atrial arrhythmias with more significant structural impairment, but this attitude requires further study. FUNDunding Acknowledgement Type of funding sources: Private hospital(s). Main funding source(s): VAVIA: IGS202009 - Racionální algoritmus při elektivní elektrické kardioverzi fibrilace síní.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.